| Autor: |
Pribut, Nicole, D’Erasmo, Michael, Dasari, Madhuri, Giesler, Kyle E., Iskandar, Sabrina, Sharma, Savita K., Bartsch, Perry W., Raghuram, Akshay, Bushnev, Anatoliy, Hwang, Soyon S., Burton, Samantha L., Derdeyn, Cynthia A., Basson, Adriaan E., Liotta, Dennis C., Miller, Eric J. |
| Zdroj: |
Journal of Medicinal Chemistry; September 2021, Vol. 64 Issue: 17 p12917-12937, 21p |
| Abstrakt: |
Tenofovir (TFV) is the cornerstone nucleotide reverse transcriptase inhibitor (NtRTI) in many combination antiretroviral therapies prescribed to patients living with HIV/AIDS. Due to poor cell permeability and oral bioavailability, TFV is administered as one of two FDA-approved prodrugs, both of which metabolize prematurely in the liver and/or plasma. This premature prodrug processing depletes significant fractions of each oral dose and causes toxicity in kidney, bone, and liver with chronic administration. Although TFV exalidex (TXL), a phospholipid-derived prodrug of TFV, was designed to address this issue, clinical pharmacokinetic studies indicated substantial hepatic extraction, redirecting clinical development of TXL toward HBV. To circumvent this metabolic liability, we synthesized and evaluated ω-functionalized TXL analogues with dramatically improved hepatic stability. This effort led to the identification of compounds 21and 23, which exhibited substantially longer t1/2values than TXL in human liver microsomes, potent anti-HIV activity in vitro, and enhanced pharmacokinetic properties in vivo. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
